The important metabolic role of FGF15/19 is reflected by the following: the dysregulation of FGF19 has been associated with inflammatory bowel disease [16], type II diabetes, obesity [17], non-alcoholic fatty liver disease (NAFLD) [18], and in a wide range of cholestasis spectrum [19]. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatotic liver disease.